Vir Biotechnology Inc (VIR)

$11.39 -0.06 (-0.57%)
Market Cap 1.93B
Revenue (ttm) 68.56M
Net Income (ttm) -437.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -638.84%
Debt to Equity Ratio 0.00
Volume 1,152,000
Avg Vol 1,824,904
Day's Range N/A - N/A
Shares Out 169.22M
Stochastic %K 72%
Beta 1.63
Analysts Strong Sell
Price Target $20.78

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibod...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 906 4324
Website: www.vir.bio
Address:
1800 Owens Street, Suite 900, San Francisco, United States
deezstocks3
deezstocks3 Sep. 4 at 5:37 PM
$VIR happy Friday bulls 😎
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 4 at 1:08 PM
$VIR Corient Private Wealth LP purchased 310,548 shares of Vir Biotechnology worth approximately $3.17 million, representing about 0.18% of the company. Institutional investors collectively own 65.32% of Vir’s stock.
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 4 at 12:10 PM
$VIR Man Group plc opened a new position in Vir Biotechnology (NASDAQ:VIR) during the second quarter, buying 150,688 shares worth about $1,536,000, according to Holdings Channel.com
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 4 at 12:07 PM
$VIR Bank of New York Mellon Corp opened a new position in Vir buying $7.08 of shares.
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 4 at 8:26 AM
$VIR $12+ would be nice going into the weekend, in fairness we’ve held well since we went above $11.
0 · Reply
Dr_MoMo
Dr_MoMo Sep. 3 at 1:17 PM
$VIR ESMO congress coming soon with submission deadline on September 8th. VIR will likely present phase 1 dose escalating data for VIR-5818 to treat colorectal cancer and breast cancer. This could be a huge catalyst!
1 · Reply
Mhand
Mhand Sep. 3 at 12:54 PM
$VIR Yesterday's Off-Exchange Short Volume was 1,197,975 shares. Off-Exchange Short Volume Ratio was 82.28 %. https://fintel.io/ss/us/vir
0 · Reply
deezstocks3
deezstocks3 Sep. 2 at 8:10 PM
$VIR volume today was 3M. Here’s a live look at the trading desk for our fav shorts at the moment… HER2 data incoming… tick tock ⏰
0 · Reply
deezstocks3
deezstocks3 Sep. 2 at 4:42 PM
$XBI take a look at the short squeeze forming over at $VIR. Several catalysts coming up this quarter and next and with 19M shares short and 11-13 days to cover these rats are starting to get nervous.
0 · Reply
Mhand
Mhand Sep. 2 at 3:19 PM
$VIR Looks like they may have burned through all of the available short shares. All Dark Pool and naked shorting likely now.
0 · Reply
Latest News on VIR
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Aug 31, 2026, 4:05 PM EDT - 6 days ago

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley

2026-08-06T11:28:16.000Z - 4 weeks ago

Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley

Vir Biotechnology price target lowered to $19 from $21 at Leerink

2026-08-06T10:17:08.000Z - 4 weeks ago

Vir Biotechnology price target lowered to $19 from $21 at Leerink

Vir Biotechnology reports Q2 EPS 47c vs. (80c) last year

2026-08-05T20:51:14.000Z - 4 weeks ago

Vir Biotechnology reports Q2 EPS 47c vs. (80c) last year

Vir Biotechnology Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 weeks ago

Vir Biotechnology Earnings Call Transcript: Q2 2026

Vir Biotechnology Slides: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 weeks ago

Vir Biotechnology Slides: Q2 2026

Vir Biotechnology Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 weeks ago

Vir Biotechnology Earnings release: Q2 2026

Vir Biotechnology Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 weeks ago

Vir Biotechnology Quarterly report: Q2 2026

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Aug 5, 2026, 4:05 PM EDT - 4 weeks ago

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Vir Biotechnology CFO Jason O’Byrne to depart

2026-07-24T12:35:30.000Z - 6 weeks ago

Vir Biotechnology CFO Jason O’Byrne to depart

Vir Biotechnology Announces Chief Financial Officer Transition

Jul 24, 2026, 8:30 AM EDT - 6 weeks ago

Vir Biotechnology Announces Chief Financial Officer Transition

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

Jul 22, 2026, 4:05 PM EDT - 6 weeks ago

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley

2026-06-11T11:25:08.000Z - 2 months ago

Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley

MIRM

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

Jun 10, 2026, 4:05 PM EDT - 2 months ago

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

Vir Biotechnology Transcript: AGM 2026

May 26, 2026, 12:00 PM EDT - 3 months ago

Vir Biotechnology Transcript: AGM 2026

Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial

2026-05-18T20:15:10.000Z - 3 months ago

Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

May 18, 2026, 4:05 PM EDT - 3 months ago

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

Vir Biotechnology Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:20 PM EDT - 3 months ago

Vir Biotechnology Transcript: Bank of America Global Healthcare Conference 2026

Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley

2026-05-08T14:13:29.000Z - 4 months ago

Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley

Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year

2026-05-07T00:48:04.000Z - 4 months ago

Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year

Vir Biotechnology Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Vir Biotechnology Earnings Call Transcript: Q1 2026

Vir Biotechnology Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Vir Biotechnology Earnings release: Q1 2026

Vir Biotechnology Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Vir Biotechnology Slides: Q1 2026

Vir Biotechnology Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Vir Biotechnology Quarterly report: Q1 2026

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 6, 2026, 4:05 PM EDT - 4 months ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

May 5, 2026, 4:05 PM EDT - 4 months ago

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Apr 23, 2026, 4:05 PM EDT - 4 months ago

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Vir Biotechnology closes global collaboration agreement with Astellas Pharma

2026-04-16T13:17:10.000Z - 4 months ago

Vir Biotechnology closes global collaboration agreement with Astellas Pharma

SNY

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Apr 16, 2026, 8:05 AM EDT - 4 months ago

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Vir Biotechnology Proxy statement: Proxy filing

Vir Biotechnology Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Vir Biotechnology Proxy statement: Proxy filing

Vir Biotechnology announces first patient dosed in Phase 1 trial of VIR-5500

2026-04-13T12:40:25.000Z - 4 months ago

Vir Biotechnology announces first patient dosed in Phase 1 trial of VIR-5500

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Apr 13, 2026, 8:05 AM EDT - 4 months ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Vir Biotechnology Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 1:40 PM EDT - 6 months ago

Vir Biotechnology Transcript: Leerink Global Healthcare Conference 2026

Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright

2026-03-04T11:16:01.000Z - 6 months ago

Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright

Vir Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 3:10 PM EST - 6 months ago

Vir Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference

Vir Biotechnology to Participate in Upcoming Investor Conferences

Feb 26, 2026, 4:05 PM EST - 6 months ago

Vir Biotechnology to Participate in Upcoming Investor Conferences

Vir Biotechnology 17.65M share Secondary priced at $8.50

2026-02-26T11:16:17.000Z - 6 months ago

Vir Biotechnology 17.65M share Secondary priced at $8.50

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Feb 25, 2026, 10:31 PM EST - 6 months ago

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Vir Biotechnology announces $200M public offering of common stock

2026-02-24T21:36:44.000Z - 6 months ago

Vir Biotechnology announces $200M public offering of common stock

Vir Biotechnology Announces Proposed Public Offering of Common Stock

Feb 24, 2026, 4:05 PM EST - 6 months ago

Vir Biotechnology Announces Proposed Public Offering of Common Stock

Vir Biotechnology price target raised to $30 from $26 at Barclays

2026-02-24T19:25:40.000Z - 6 months ago

Vir Biotechnology price target raised to $30 from $26 at Barclays

Vir Biotechnology price target raised to $18 from $14 at Needham

2026-02-24T14:37:22.000Z - 6 months ago

Vir Biotechnology price target raised to $18 from $14 at Needham

Vir Biotechnology Slides: Corporate presentation

Feb 24, 2026, 7:00 AM EST - 6 months ago

Vir Biotechnology Slides: Corporate presentation

What's Happening With VIR Stock?

Feb 24, 2026, 4:10 AM EST - 6 months ago

What's Happening With VIR Stock?

Vir Biotechnology Earnings Call Transcript: Q4 2025

Feb 23, 2026, 5:30 PM EST - 6 months ago

Vir Biotechnology Earnings Call Transcript: Q4 2025

Vir Biotechnology Annual report: Q4 2025

Feb 23, 2026, 5:30 PM EST - 6 months ago

Vir Biotechnology Annual report: Q4 2025

Vir Biotechnology Earnings release: Q4 2025

Feb 23, 2026, 5:30 PM EST - 6 months ago

Vir Biotechnology Earnings release: Q4 2025

Vir Biotechnology Slides: Q4 2025

Feb 23, 2026, 5:30 PM EST - 6 months ago

Vir Biotechnology Slides: Q4 2025

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 23, 2026, 5:14 PM EST - 6 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Astellas collaborates with Vir to develop its experimental prostate cancer drug

Feb 23, 2026, 5:08 PM EST - 6 months ago

Astellas collaborates with Vir to develop its experimental prostate cancer drug

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Feb 23, 2026, 5:02 PM EST - 6 months ago

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

Feb 23, 2026, 5:00 PM EST - 6 months ago

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

Feb 9, 2026, 4:05 PM EST - 6 months ago

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

Vir Biotechnology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 7 months ago

Vir Biotechnology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 7 months ago

Vir Biotechnology Slides: 44th Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

Jan 12, 2026, 8:00 AM EST - 7 months ago

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:05 PM EST - 8 months ago

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

Dec 16, 2025, 4:05 PM EST - 8 months ago

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

Vir Biotechnology Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 10:50 AM EST - 9 months ago

Vir Biotechnology Transcript: Evercore ISI 8th Annual HealthCONx Conference

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

Nov 19, 2025, 4:05 PM EST - 9 months ago

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

Vir Biotechnology Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 9:00 AM EST - 9 months ago

Vir Biotechnology Transcript: Jefferies London Healthcare Conference 2025

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Nov 9, 2025, 6:07 PM EST - 10 months ago

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Nov 7, 2025, 9:00 AM EST - 10 months ago

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Vir Biotechnology Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

Vir Biotechnology Earnings Call Transcript: Q3 2025

Vir Biotechnology Quarterly report: Q3 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

Vir Biotechnology Quarterly report: Q3 2025

Vir Biotechnology Earnings release: Q3 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

Vir Biotechnology Earnings release: Q3 2025

Vir Biotechnology Slides: Q3 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

Vir Biotechnology Slides: Q3 2025

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 10 months ago

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

Nov 3, 2025, 8:00 AM EST - 10 months ago

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 22, 2025, 4:05 PM EDT - 10 months ago

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

Oct 9, 2025, 4:05 PM EDT - 11 months ago

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 25, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Vir Biotechnology Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Earnings Call Transcript: Q2 2025

Vir Biotechnology Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Quarterly report: Q2 2025

Vir Biotechnology Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Earnings release: Q2 2025

Vir Biotechnology Slides: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Slides: Q2 2025

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Aug 6, 2025, 8:05 AM EDT - 1 year ago

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 31, 2025, 8:05 AM EDT - 1 year ago

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Jul 24, 2025, 8:05 AM EDT - 1 year ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 22, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

20 stocks you should avoid — no matter how well the market does

Jun 11, 2025, 7:00 AM EDT - 1 year ago

20 stocks you should avoid — no matter how well the market does

CORT CPRX CRK CRNC DDD LUMN LYV

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Vir Biotechnology Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 27, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 20, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

Vir Biotechnology Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 4:40 PM EDT - 1 year ago

Vir Biotechnology Transcript: BofA Securities 2025 Healthcare Conference

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 9, 2025, 6:00 AM EDT - 1 year ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Earnings Call Transcript: Q1 2025

Vir Biotechnology Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Quarterly report: Q1 2025

Vir Biotechnology Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Earnings release: Q1 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 24, 2025, 9:30 AM EDT - 1 year ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Vir Biotechnology Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Vir Biotechnology Proxy statement: Proxy Filing

Vir Biotechnology Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Vir Biotechnology Proxy statement: Proxy Filing

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Mar 21, 2025, 7:10 AM EDT - 1 year ago

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Mar 13, 2025, 8:05 AM EDT - 1 year ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Vir Biotechnology Earnings Call Transcript: Q4 2024

Vir Biotechnology Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Vir Biotechnology Annual report: Q4 2024

Vir Biotechnology Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Vir Biotechnology Earnings release: Q4 2024

Vir Biotechnology Slides: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Vir Biotechnology Slides: Q4 2024

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Feb 12, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

deezstocks3
deezstocks3 Sep. 4 at 5:37 PM
$VIR happy Friday bulls 😎
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 4 at 1:08 PM
$VIR Corient Private Wealth LP purchased 310,548 shares of Vir Biotechnology worth approximately $3.17 million, representing about 0.18% of the company. Institutional investors collectively own 65.32% of Vir’s stock.
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 4 at 12:10 PM
$VIR Man Group plc opened a new position in Vir Biotechnology (NASDAQ:VIR) during the second quarter, buying 150,688 shares worth about $1,536,000, according to Holdings Channel.com
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 4 at 12:07 PM
$VIR Bank of New York Mellon Corp opened a new position in Vir buying $7.08 of shares.
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 4 at 8:26 AM
$VIR $12+ would be nice going into the weekend, in fairness we’ve held well since we went above $11.
0 · Reply
Dr_MoMo
Dr_MoMo Sep. 3 at 1:17 PM
$VIR ESMO congress coming soon with submission deadline on September 8th. VIR will likely present phase 1 dose escalating data for VIR-5818 to treat colorectal cancer and breast cancer. This could be a huge catalyst!
1 · Reply
Mhand
Mhand Sep. 3 at 12:54 PM
$VIR Yesterday's Off-Exchange Short Volume was 1,197,975 shares. Off-Exchange Short Volume Ratio was 82.28 %. https://fintel.io/ss/us/vir
0 · Reply
deezstocks3
deezstocks3 Sep. 2 at 8:10 PM
$VIR volume today was 3M. Here’s a live look at the trading desk for our fav shorts at the moment… HER2 data incoming… tick tock ⏰
0 · Reply
deezstocks3
deezstocks3 Sep. 2 at 4:42 PM
$XBI take a look at the short squeeze forming over at $VIR. Several catalysts coming up this quarter and next and with 19M shares short and 11-13 days to cover these rats are starting to get nervous.
0 · Reply
Mhand
Mhand Sep. 2 at 3:19 PM
$VIR Looks like they may have burned through all of the available short shares. All Dark Pool and naked shorting likely now.
0 · Reply
Mhand
Mhand Sep. 2 at 2:54 PM
$VIR A real tug-of-war with the shorts. Pressure is building! They keep digging a deeper hole because no one is willing to sell their shares. Definitely not 19 million shares.
0 · Reply
wintogether
wintogether Sep. 2 at 2:31 PM
$VIR going up for no reason. Or maybe there is a reason that we just don't know?
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 2 at 1:38 PM
$VIR $11.92 currently, $12 today perhaps?
1 · Reply
PCIntern
PCIntern Sep. 2 at 1:36 PM
$VIR here we go maybe perhaps.
0 · Reply
JamieJJ
JamieJJ Sep. 2 at 1:11 PM
$VIR Nice trend and price action! if it can back to $11.3 I want to buy. Or just buy it directly!
0 · Reply
TrollenStock
TrollenStock Sep. 2 at 11:42 AM
$VIR We have a massive technical outbreak coming today. MA200 on weekly 🚀
0 · Reply
Mhand
Mhand Sep. 2 at 11:36 AM
$VIR Today may see a strong retaliation by the shorts. Short Interest has climbed to 19,595,909 shares or 15.10 % of the float. Dark Pool short volume is 821,362 shares or 74.66% of Dark Pool volume. These are the highest ratios I've seen since I started watching this stock. I believe higher than the WallStreetBets runup in 2021. 2.4 million shares back on the table for shorting this morning. If we can get some decent buying volume, the short squeeze could be massive. https://fintel.io/ss/us/vir
0 · Reply
sittingonagoldmine
sittingonagoldmine Sep. 1 at 8:33 PM
$VIR Just a repost for those who missed it. Good luck to all VIR long-term holders!
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 1 at 7:04 PM
$VIR at the high of the year now.
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 1 at 6:58 PM
$VIR $11.54 could we beat the high of the year $11.66, if so that would be bullish
0 · Reply
deezstocks3
deezstocks3 Sep. 1 at 3:18 PM
$VIR shorts are starting to think twice…
2 · Reply
Dunnieboy1
Dunnieboy1 Sep. 1 at 2:41 PM
$VIR up 5%, not far off the year high of $11.66
0 · Reply